HLB announced on the 25th that the results of the first phase 3 global clinical trial of liver cancer using riboceranib, which holds global rights, and Kamrellizumab of Hangseo Pharmaceutical in China, were published in "The Lancet," the world's most prestigious medical journal. It is the first time that anti-cancer drugs from domestic companies have been on Lancet.
Please refer to the following website for further details: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00961-3/fulltext